The company posted a net loss of $32.1m, or $0.57 per diluted share for the first quarter of 2011, compared to $34.08m, or $0.66 per diluted share, for the same period in 2010.
For the first quarter of 2011, InterMune‘s loss form operations was $30.35m, compared to $32.17m for the same period prior year.
InterMune president, chairman and CEO Dan Welch said first quarter events were highlighted by the announcement on 3 March that the European Commission had granted marketing authorization for Esbriet (pirfenidone) for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis, or IPF.
"The approval of Esbriet not only marks an historic moment in the treatment of IPF patients, but also an exciting new chapter for our company as we now transition to become an international commercial organization," Welch said.
"We are working diligently to make Esbriet available to European patients as soon as possible, beginning with Germany in September 2011."